Inhibitec

Towards a novel disruptive therapy in psoriasis and psoriatic arthritis



FIDBAN
20ª Ronda de inversores
Santander
30.05.24

The scope

Psoriasis is an autoimmune disease of the skin that affects about 2% of the global population (≈ 160 million of patients). According to WHO: Chronic, noncommunicable, painful, disfiguring and disabling with **no cure.**







30% of patients with psoriasis will develop **Psoriatic Arthritis (PsA)**



Higher economic burden when including **comorbidities** (30-194% increase).

Prevalence rise. It will double in the next 5 years.

Source: Polaris Market Research (2022-2030)

The problem and the opportunity

Inhibitec

Autoimmune diseases, and in particular psoriasis and PsA, are mediated by a subset of immune cells named CD4 T lymphocytes.

Patients with PsA show an increase in the activity of pathogenic pro-inflammatory Th17 cells and a compromised activity of protective Tregs.

The existing biologicals used to treat psoriasis and PsA block the action of cytokines such as **TNFα** or **the Th17 axis** (IL-23 / IL-17A).

Th17-mediated Chronic Inflammatory Diseases



~ 40% of PsA patients do not reach a **minimum level of efficacy** (ACR 20% joint response level) and the appearance of **drug resistances** in patients that initially respond to treatments is frequent.

CURRENT SOLUTIONS

Current solutions do not have successful results on patients, and most of the therapies will expire their intellectual property protection soon, which will reduce their interest.

NOVEL THERAPIES PIPELINE

Lack of variability among biological targets. The current landscape is characterized by few targets, offering little differentiation among solution .

SUCCESS

Patients develop secondary resistance and ling-term side effects.
There is a need to find new molecular targets and therapies.

First-in-class target, first-in class approach

Inhibitec has identified **BAMBI** as a key molecule during PsA development and produced an inhibitory mAb (B101.37)

Anti-Bambi treatment has double effect on psoriasis and PsA: It **enhances Treg** differenciation **AND inhibits pro-inflammatory cells.**





Comparative analysis: Broader and better treatment

Inhibitec

COMPANY	**Abbvie** *(Several companies)*	**Novartis** **Lilly** **Leo Pharma** **UBC**	**Janssen** **Almirall** **Janssen**	**Inhibitec**
NAME	***Adalimumab***	***Secukimumab*** ***Ixekizumab*** ***Brodalumab*** ***Bimekizumab***	***Ustekinumab*** ***Tildrakizumab*** ***Guselkumab***	***Anti-BAMBI***
TARGET	**TNFα**	**IL-17A** **IL-17RA** **IL17A/IL17F**	**IL-23p40** **IL-23p19**	**BAMBI**

Options in the market	Multiple	Multiple	Multiple	**Only Inhibitec**
Patent lifespan	Biosimilars	Close to expire	Close to expire	**Newer**
Effect on multiple cell types	-	-	-	✓
Therapeutic effect on psoriasis	++	++	++	+++
Therapeutic effect on PsA	+	+	+	+++

Comparative analysis: Broader and better treatment

Inhibitec



Mannan-induced PsA model

↓

IL-17-dependent

IL-21 induced PsO model

↓

IFNy-dependent

Broader therapeutic activity **than α-IL-17 mAbs** in **Psoriasis**

Humanized anti-BAMBI mAb

Inhibitec

Humanization of anti-BAMBI mAb has been completed and its therapeutic effect validated (PoC)









Non-treated

α-BAMBI mAb-5

Ongoing strong ambitious plan for IP reinforcement and extension

Pre-clinical phase (no-regulatory)

Inhibitec

Pilot toxicology in rodents

Acute toxicity (3 days upon administration)



Long-term toxicity (3 weeks upon administration)



Working plan (2024-2027)

Inhibitec

90%
Non-regulatory
pre-clinical studies



up to 2M€ awarded since 2019

European Innovation Council

NATIONAL PSORIASIS FOUNDATION

CDTI neotec

enisa

GOBIERNO de CANTABRIA
VICEPRESIDENCIA
CONSEJERÍA DE UNIVERSIDADES, IGUALDAD, CULTURA Y DEPORTE

MINISTERIO DE CIENCIA E INNOVACIÓN

Financiado por la Unión Europea NextGenerationEU

Plan de Recuperación, Transformación y Resiliencia

AGENCIA ESTATAL DE INVESTIGACIÓN

Working plan (2024-2027)

Inhibitec

Expenses	2024	2025	2026	2027	Total
Personnel	200.000	200.000	200.000	500.000	1.100.000
Pre-clinical studies	2.000.000	1.000.000			3.000.000
Stable cell development and project design	500.000				500.000
Process development and analytic methods		2.000.000			2.000.000
Scale up and GMP manufacturing		2.000.000	3.000.000		5.000.000
Consumables	100.000	100.000	100.000	100.000	400.000
IP			20.000		20.000
Phase I				400.000	400.000
Total	2.800.000	5.300.000	3.320.000	1.000.000	**12.020.000**



Total funded need 12M €

Current funding round 2M€

Milestones

Inhibitec

Milestones accomplished:



Multidisciplinary team

Inhibitec

Research team

Victoria Casado Medrano, PhD
CSO Inhibitec

Vincenzo Cappitelli, PhD
Postdoctoral Researcher

Paula Perez
PhD candidate

Jorge Ruiz del Rio, PhD
Postdoctoral Researcher

Mónica Urcelay
Lab Technician

Sara del Palacio
Lab Technician

Business Advisors

Gabriel Mesquida Jaume
CEO Inhibitec

Eduardo Quemada McGuckian
CFO Inhibitec

External Advisor Board

Gabriel Nuñez, MD, PhD
University of Michigan

Stephane Schurmans, MD, PhD
University of Liège

Scientific Advisors

Ramon Merino, MD, PhD
Scientific advisor

Jesús Merino, MD, PhD
Scientific Advisor



Carlo Chizzolini, MD, PhD
University of Geneva

Miguel Lopez Botet, MD, PhD
Pompeu Fabra University

Together, we are committed to making a positive impact and transforming the future of PsO and PsA.

Inhibitec

Instituto de Biomedicina y
Biotecnología de Cantabria
Tfn: 942-502799
C/ Albert Einstein 22, 39011 Santander (Spain)
gm@inhibitec.com
victoria.casado@inhibitec.com

Who is supporting us